

Table S6. Percentage of hyper Vif derivatives in stable A3H humanized mice infected with HIV-1 NLCSFV3.

Mouse no.*	Donor lot*	<i>APOBE3H</i> haplotype		# Analyzed sequence	# Vif derivatives with anti-A3H activity†	% Vif with anti-A3H-II activity‡
22	H	I / II	Stable	58	32	55.2
23	H	I / II	Stable	60	39	65.0
24	H	I / II	Stable	64	45	70.3
25	H	I / II	Stable	61	29	47.5
Average				243	145	59.7
SEM						5.1

* Identical to Figure 3 and Table S5.

† Number of Vif derivatives acquiring anti-A3H-II activity (Figures 3C-3E).

‡ Percentage of Vif derivatives acquiring anti-A3H-II activity.